These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34241941)

  • 1. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
    Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
    Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine Histiocytic and Hemophagocytic Histiocytic Sarcomas Display
    Yang YT; Engleberg AI; Kapoor I; Kitagawa K; Hilburger SA; Thaiwong-Nebelung T; Yuzbasiyan-Gurkan V
    Genes (Basel); 2024 Aug; 15(8):. PubMed ID: 39202410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
    Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
    Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
    Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
    J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
    Thaiwong T; Sirivisoot S; Takada M; Yuzbasiyan-Gurkan V; Kiupel M
    Vet Comp Oncol; 2018 Jun; 16(2):220-228. PubMed ID: 28929581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
    LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
    Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib.
    Takada M; Smyth LA; Hix JM; Corner SM; Kiupel M; Yuzbasiyan-Gurkan V
    Comp Med; 2019 Feb; 69(1):22-28. PubMed ID: 30717820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
    Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating Mutations in
    Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
    Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterisation of cell lines and xenograft mouse models of canine systemic histiocytosis and disseminated histiocytic sarcoma.
    Hirabayashi M; Chambers JK; Kishimoto TE; Nguyen SV; Ishikawa Y; Rimpo K; Nakayama H; Uchida K
    Vet Comp Oncol; 2022 Jun; 20(2):465-475. PubMed ID: 34907644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
    Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of the two-base insertion mutation in the TP53 gene in canine histiocytic sarcoma.
    Asada H; Tomiyasu H; Okada K; Chambers JK; Goto-Koshino Y; Uchida K; Kagawa Y; Ohno K; Tsujimoto H
    Res Vet Sci; 2019 Jun; 124():57-60. PubMed ID: 30852355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
    Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
    Yamazaki H; Takagi S; Hosoya K; Okumura M
    Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders.
    Hirabayashi M; Chambers JK; Tani A; Tomiyasu H; Motegi T; Rimpo K; Nakayama H; Uchida K
    Vet Comp Oncol; 2022 Sep; 20(3):587-601. PubMed ID: 35278028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
    Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
    BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.